Most Clicked StoriesMore >


Report: Specialty-drug prices likely to drive up medical inflation

PCMA SmartBrief | Jun 30, 2015

The FDA is approving more specialty drugs than traditional drugs, and high prices on specialty drugs to treat hepatitis C, cancer and high cholesterol are likely to have an effect on medical costs and inflation, according to a new PricewaterhouseCoopers report. MedCityNews.com (06/29)


Some domestic partners might lose benefits after Supreme Court marriage ruling

PCMA SmartBrief | Jun 29, 2015

Proposed health insurer mergers raise antitrust concerns

PCMA SmartBrief | Jun 29, 2015

PCMA: Rx copay caps are government price controls

PCMA SmartBrief | Jul 01, 2015

Employers, unions seek repeal of ACA Cadillac tax

PCMA SmartBrief | Jul 02, 2015

Novartis to link pricing of heart failure drug to clinical outcomes

PCMA SmartBrief | Jul 01, 2015

Price could block patient access to PCSK9 inhibitors, experts say

PCMA SmartBrief | Jul 01, 2015

Cadillac tax exacerbates contract disputes

PCMA SmartBrief | Jun 30, 2015

Survey: Nearly 50% of doctors misinformed about abuse-deterrent opioids

PCMA SmartBrief | Jun 29, 2015

Purdue Pharma withdraws FDA application for abuse-deterrent OxyContin drug

PCMA SmartBrief | Jul 01, 2015


Find PCMA SmartBrief Issues by Date:





Sign up for PCMA SmartBrief



Designed specifically for PBM industry professionals, PCMA SmartBrief is a FREE, daily e-mail newsletter. It provides the the most relevant and actionable PBM industry news in a quick, easy to read format. Learn more